Literature DB >> 11091516

Low Grade Amplification of MDM2 Gene in a Subset of Human Breast Cancers without p53 Alterations.

.   

Abstract

MDM2 protein is thought to bind to p53 tumor suppressor protein leading to inhibition of p53-mediated transactivation. Amplification of the MDM2 gene has been frequently observed in human sarcoma, and relevant overexpression of the MDM2 protein is assumed to contribute to tumorigenesis through inactivation of the p53 function. In order to determine whether MDM2 amplification plays a role in the development of human breast cancer without genetic alteration of p53, we analyzed, MDM2 gene amplification by quantitative hybridization and genetic alteration of p53, in 32 primary tumors and 26 metastatic lymph nodes. Low grade amplification of the MDM2 gene (2-6 fold) was observed in four cases, none of which showed even subtle genetic alterations of p53 or loss of alleles on 17p. Moreover, in three of the four cases with MDM2 gene amplification, the level of gene amplification in the metastatic lymph nodes was slightly higher than that in the primary tumors. These results, taken together with previous findings, suggest that a subset of breast cancers without genetic alteration of p53 may also arise by inactivation of the p53 function through interaction with the overexpressed MDM2 protein induced by gene amplification.

Entities:  

Year:  1994        PMID: 11091516     DOI: 10.1007/BF02967038

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  27 in total

1.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.

Authors:  J Bargonetti; P N Friedman; S E Kern; B Vogelstein; C Prives
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

3.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line.

Authors:  L Cahilly-Snyder; T Yang-Feng; U Francke; D L George
Journal:  Somat Cell Mol Genet       Date:  1987-05

4.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

6.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

7.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.

Authors:  T Sato; A Tanigami; K Yamakawa; F Akiyama; F Kasumi; G Sakamoto; Y Nakamura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

9.  Frequent loss of heterozygosity at the MCC locus on chromosome 5q21-22 in sporadic colorectal carcinomas.

Authors:  Y Miki; I Nishisho; Y Miyoshi; A Horii; H Ando; T Nakajima; J Utsunomiya; Y Nakamura
Journal:  Jpn J Cancer Res       Date:  1991-09

10.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  1 in total

1.  MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.

Authors:  M Higashiyama; O Doi; K Kodama; H Yokouchi; T Kasugai; S Ishiguro; K Takami; T Nakayama; I Nishisho
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.